Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FCER2 | P06734 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16328286 | 0.87 | GAA (0.38) | GAAMMP13PSEN1PSEN2APH1B | |
| SCHEMBL12401222 | 0.86 | HPGD (0.47) | GAAKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL12401235 | 0.79 | UTS2R (0.45) | GAAKMT2ARAB9AMEN1POLB | |
| SCHEMBL12404589 | 0.77 | MEN1 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL12401266 | 0.75 | RAB9A (0.53) | GAARAB9AALDH1A1 | |
| SCHEMBL12401232 | 0.74 | CYP1A2 (0.49) | POLBALDH1A1 | |
| SCHEMBL14943558 | 0.73 | HPGD (0.48) | GAAPOLBALDH1A1 | |
| SCHEMBL12467393 | 0.71 | HPGD (0.49) | GAAKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL12401071 | 0.71 | ALDH1A1 (0.37) | MMP13ALDH1A1 | |
| SCHEMBL12401154 | 0.71 | PHF8 (0.39) | MMP13POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | GAA 771/4885MMP13 381/4885PSEN1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.